INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Tax withholdingVerified data

Szela Mary T reported TLSI

Director, CEO and President · TriSalus Life Sciences, Inc. · Common Stock

Side
F
Value
$12K
Shares
2,693
Price
$4.38
Executed
Oct 5, 2026
Disclosed
Oct 7, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 5 executedOct 7, 2026 disclosed

TLSI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$12K reported value · 0.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TLSI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    31
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,299
    296 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    31
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,387
    316 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    31
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Open-market sale
    		SELL$1,427
    325 sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    28
    FA
    Frankenius Equity AB10% Owner
    TLSITriSalus Life Sciences, Inc.
    Derivative conversion
    		C—
    759.0K sh
    		Jul 31, 2025Apr 20, 2026
    traded Jul 31, 2025
    		+263dSEC FORM 4

    Evidence

    24
    FA
    Frankenius Equity AB10% Owner
    TLSITriSalus Life Sciences, Inc.
    Derivative conversion
    		C—
    230.0K sh
    		Jul 31, 2025Apr 20, 2026
    traded Jul 31, 2025
    		+263dSEC FORM 4

    Evidence

    17
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    80.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    PD
    Patience DavidChief Financial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    65.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    PD
    Patience DavidChief Financial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    130.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    DJ
    Devlin JodiChief of Clinical Operations
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    50.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    CF
    Cox Bryan F.Chief of Research
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    40.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    DJ
    Devlin JodiChief of Clinical Operations
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    60.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    17
    MR
    Marshak RichardChief Commercial Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    120.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    21
    SJ
    Stevens JenniferChief Regulatory Officer
    TLSITriSalus Life Sciences, Inc.
    Grant or award
    		A—
    50.0K sh
    		Nov 24, 2025Nov 25, 2025
    traded Nov 24, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-065323
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 5, 2026
    Published
    Oct 7, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 02:12 UTC

    Extracted facts

    Filer
    Szela Mary T
    Role
    Director, CEO and President
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    TriSalus Life Sciences, Inc.
    Ticker
    TLSI
    Shares
    2,693
    Price per share
    $4.38
    Value
    $11,795
    Execution date (reported)
    Oct 5, 2026
    Owned after transaction
    1.07M shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,693
    • Price: $4.38

    = $11,795

    What this establishes

    Szela Mary T filed this Form 4 reporting a tax withholding of TLSI on Oct 5, 2026. It became public on Oct 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO and President
    Szela Mary Tcik:0001410289
    Issuer
    TriSalus Life Sciences, Inc.cik:0001826667

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.